Beijing Hotgen Biotech Co.,Ltd.
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Beijing Rejing Biotechnology Co., Ltd., established in June 2005, is a biotechnology high-tech enterprise with the mission of "developing biotechnology for the benefit of human health". The company continuously explores independent and innovative diagnostic technology platforms, actively develops and expands liquid biopsy cancer early screening technology, and establishes a multi omics diagnostic technology platform that includes protein markers, exosomes, and DNA methylation; At the same time, the Future Technology Research Institute will be established to explore cutting-edge technologies, actively layout the biopharmaceutical fields such as antibody drugs, live bacterial drugs, and exosomes drugs, and create a full industry chain development strategy from diagnosis to treatment. In the field of clinical diagnosis, the company has multiple cutting-edge innovative technologies and products, and has established Beijing Key Laboratory for Biological Emergency and Clinical POCT, Beijing Enterprise Technology Center, and postdoctoral research workstations; After years of development, the company has established eight major clinical diagnostic product technology platforms in the field of clinical diagnosis, including the research and development platform for bioactive raw materials, sugar capture technology platform, magnetic particle chemiluminescence technology platform, upconversion luminescence technology platform, colloidal gold immunochromatography technology platform, enzyme-linked immunosorbent technology platform, molecular diagnostic technology platform, and instrument research and development technology platform; Establishing a strategic layout from high-precision upconversion luminescence POCT (UPT series) platform to small, medium-sized, and fully automated single person chemiluminescence platform (MQ60 instrument series), and then to large-scale high-throughput fully automated chemiluminescence platform (C900, C2000, C3000), achieving the enterprise strategy of achieving full scenario application of immune diagnosis from the grassroots medical market to the high-end medical market. The detection menu of the company has covered the detection of inflammation, infection, cardiovascular and cerebrovascular diseases, bone metabolism, thyroid hormone, diabetes, hypertension, hepatitis, liver cancer, other tumors and other diseases; And it has achieved the widespread promotion and application of single sample testing in the domestic grassroots medical market, as well as the application of "liver cancer early diagnosis triple check products (AFP, AFP L3%, DCP)" in most large benchmark tertiary hospitals. As one of the first enterprises to obtain market access for COVID-19 antigen self-test products in Germany in 2021, the company always practices the core value of "quality determines the life and death of enterprises", and continues to provide excellent products to the global market; COVID-19 Self testing Reagent has been successively registered/filed by European Union CE, Germany BfArM, France ANSM, Britain MHRA, Thailand TFDA, Singapore Health Science Agency HSA, Brazil Health Agency ANVISA and other global mainstream products, and has been exported to nearly 40 countries and regions in the world, such as Germany, France, Italy, Austria, Hong Kong, Singapore, Vietnam, Thailand, Brazil, Peru and other countries and regions. It is widely recognized and has become the mainstream product in the European household self testing market. The company continues to expand its business and establish subsidiaries or offices in key markets such as Europe, India, and the Americas. The company was listed on the Science and Technology Innovation Board in 2019 and is the first enterprise in the IVD field to be listed on the Science and Technology Innovation Board. The company was awarded the Most Valuable Science and Technology Innovation Board Listed Company in 2021, and was listed on the Top 100 Listed Companies on the Science and Technology Innovation Board in 2022. It was also listed on the Top 500 New Economy Enterprises in China in 2021, recognized as a "Little Giant" enterprise in Beijing, and selected as one of the Top 100 Private Enterprises in Beijing. The R&D team of Rejing was awarded the titles of "2020 Beijing Model Collective" and "2022 National Worker Pioneer". The company always focuses on technological innovation, continuously exploring new diagnostic technologies and discovering new diagnostic biomarkers; At the same time, we continuously explore new business areas and accelerate our comprehensive layout in the biopharmaceutical field. Using technology to support the national "14th Five Year Plan" development strategy and strive to build a community of human health!. |
| Headquarter | Beijing |
| Establish Date | 6/23/2005 |
| Listed Code | 688068.SH |
| Listed Date | 9/30/2019 |
| Chairman | Lin Changqing. |
| CEO | Lin Changqing. |
| Website | www.hotgen.com.cn |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
